Clinical Trial

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 9, 2026 (before its estimated January 12, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight/obese adult subjects. The safety and tolerability of HDM1002 with metformin, empagliflozin, midazolam, valsartan, and warfarin when given separately or together will also be evaluated
Trial Details
NCT Number NCT07331389
Lead Sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions Overweight Subject, Healthy Subjects
Enrollment 111 participants
Start Date 2025-09-24
Primary Completion 2026-01-12 (estimated)
Study Completion 2026-06-13 (estimated)
Updated on ClinicalTrials.gov 2026-01-09